logo

Immunogen Inc (IMGN)



Trade IMGN now with
  Date
  Headline
10/19/2020 8:50:44 AM ImmunoGen, Huadong Medicine Announce Strategic Collaboration To Develop, Commercialize Mirvetuximab Soravtansine
10/5/2020 6:38:16 AM ImmunoGen Announces FDA Breakthrough Therapy Designation For IMGN632
9/17/2020 3:03:58 AM ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort
7/31/2020 6:40:22 AM ImmunoGen Q2 Net Loss $24.3 Mln Or $0.14/shr Vs. Net Loss $43.4 Mln Or $0.29/shr Last Year
6/1/2020 8:07:30 AM ImmunoGen Names Stacy Coen SVP And Chief Business Officer
5/1/2020 6:42:35 AM ImmunoGen Q1 Net Loss $29.1 Mln Vs Net Loss $43.8 Mln Last Year
2/14/2020 10:24:05 AM Stock Alert: ImmunoGen (IMGN)
2/14/2020 6:39:34 AM ImmunoGen Q4 EPS $0.03 Vs Loss $0.28 Last Year
1/22/2020 9:03:28 PM ImmunoGen Prices Underwritten Public Offering Of 21.33 Mln Shares At $4.25/shr
1/22/2020 4:13:29 PM ImmunoGen Announces Proposed Public Offering Of Common Stock
12/17/2019 6:34:56 AM ImmunoGen Announces Accelerated Approval Pathway For Mirvetuximab Soravtansine In Ovarian Cancer
11/1/2019 6:53:51 AM ImmunoGen Q3 Net Loss $21.8 Mln Or $0.15/Shr Vs Net Loss Of $46.8 mln Or $0.32/Shr Last Year
9/17/2019 6:43:46 AM ImmunoGen To Present Full Data And Addl Exploratory Analyses From Phase 3 FORWARD I Study
8/2/2019 6:34:19 AM ImmunoGen Q2 Net Loss $43.4 Mln Or $0.29/Shr Vs Loss $41.6 Mln Or $0.31/Shr Year-ago
6/27/2019 6:33:18 AM ImmunoGen Announces Completion Of An In-depth Operational Review
5/3/2019 6:34:59 AM ImmunoGen Q1 Loss Per Share $0.30, Same As Last Year
3/1/2019 6:43:18 AM ImmunoGen Says Phase 3 FORWARD I Study Did Not Meet Primary Endpoint